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This combined model yielded a C-Index of 0.82, indicating that the strategy
could be clinically useful fordiscriminating between the OPEN from CLOSED
pt groups. This combined strategy is convenient for noninvasively assessing
reperfusion status after TI because it involves a single MYO measurement
and a straightforward clinical indicator.
bolytic therapy (TI) at a median (25th , 75th percentile) of 162 (113, 2261 mins
after onset of symptoms. All pts had acute angiography (Cath) at 142 (96,
195) mins after TI; flow in the IRA was graded as either "OPEN", TIMI 2-3
(n = 711, or "CLOSED", TIMI 0-1 (n = 25). MYO was determined in serial
samples collected before TI (Baseline) and within 10 mins of Cath. MYO val-
ues, in ng/mL, in Baseline samples were similar for the OPEN and CLOSED
groups at 112 (51,275) and 81 (47, 195), respectively; for samples collected
at Cath, values were 915 (501, 2237) for the OPEN group and 273 (159, 855)
for the CLOSED group. MYO strategies based on: 1. MYO Value at Cath, 2.
change from baseline to Cath (Delta), and 3. rate of release (slope) were each
combined with clinical variables for discriminating OPEN from CLOSED pts.
The clinical variables examined were: time from Chest Pain (CP) to TI, time
from TI to Cath, pt weight, pt age, Mllocation, race, and intensity of CP at
Cath graded 0-10. By logistic regression, the best model for discriminating
OPEN from CLOSED pts resulted from combining the following:
patients (20%) and normal in 105. All 8 of the patients with minor elevations
of CK-M B also had elevated troponin T; CK-M B was normal in all patients
with normal troponin T. Patients with elevated troponin T levels were older
(74 ± 10 vs 63 ± 12 years, p < 0.0011 but did not differ from patients with
normal levels with respect to risk factors or other clinical features. However,
as shown in the table, coronary events occurred significantly more frequently
in patients with elevated troponin T levels:
Troponin T on admission: Normal Elevated p
Patients 105 26
Myocardial infarction 3(3%) 8(31%} <0.001
Refractory angina 9(9%) 4(15%} NS
Revascularization 32 (30%) 17 (65'10) ~0.001
Pts with cardiac events 42 (40%) 25 (96'10) <0.001
Only one of the 26 patients with elevated troponin T levels was controlled
with medical therapy alone, compared to 62 of the 105 with normal levels
(4% vs 59%, P < 0.001). The cutpoint of >0.1 j.Lg/L had a sensitivity of 50%
and a specificity of 87% in predicting refractory angina/myocardial infarction.
Conclusion: Serum troponin T levels are elevated on admission in one fifth
of unselected unstable angina patients. These patients have a very high rate
of myocardial infarction and refractory angina despite medical treatment.
and most of them undergo revascularization. Troponin T levels are an inde-
pendent and potentially useful predictor of early coronary events in unstable
angina.
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Stratergy
MYO value at Cath
CP at Cath (o-1O)
Combined Model
1797
7.46
23.95
p-value
0.0002
0.006
>0.000001
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To evaluate whether serum Troponin T (Trop-T) or CK-MB analysis could be
used to risk stratify patients with acute ischemic syndromes, admission
serum samples were obtained in 865 patients enrolled in the GUSTO-lia
study. Pts were stratified on admission into ST elevation (n = 531) and non-
ST elevation (n = 334) groups. CK-MB (mass assay) and Trop-T (immunoas-
say) were measured by an enzymatic core laboratory. The median (25th, 75th
parcentile) serum CK-MB was 2.9 (0.9, 8.2) ng/ml in the non-ST and 4.0 (1.5,
14.1) ng/ml in the ST elevation group. Corresponding Trop-T levels were 0.05
(0.01, 0.27) ng/ml and 0.04 (0.01, 0.33) ng/ml. respectively. Elevated levels
of CK-MB (>7 ng/mll were seen in 33% and Trop-T levels >0.1 ng/ml were
seen in 36% pts. Regression analysis documented that Trop-T levels were
strongly associated with mortality (p < 0.0001 ), while CK-M B levels were less
strongly associated (p = 0.03). In a regression model of both serum markers
and mortality, CK-MB added no information (p = 0.9) after the Trop-T lev-
els were included. Higher admission Trop-T levels were also associated (p
= 0.005) with a poor clinical outcome using a composite endpoint of death,
late (> 18 hours after admission) myocardial infarctionlreinfarction (MI), car-
diogenic shock or heart failure (CHF), while only a weak relationship was ob-
served with CK-MB (p = 0.07). Outcomes based on admission Trop-T levels
>0.1 ng/ml (Pos) or <0.1 (Neg) were as shown:
Non-ST Group ST elevation Group
Trop-T Neg Trop-T Pas Trop-T Neg Trop-T Pas
Outcomes N = 201 N ~ 123 N = 324 N = 176
Death 1% 9% 5% 12%
Shock 2% 6% 3% 9%
MI 6% 11% 5% 7%
CHF 7% 16% 10% 15%
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1738-1 1 Five Year Trends in the Treatment of Angiographically
Documented Coronary Artery Disease: Experience of
a Tertiary Care Center
Glenn N. Levine, Jonathan D. Bier, Michael Stucci, Thomas J. Ryan, Alice
K. Jacobs. Boston University Medical Center. Boston, MA
To determine the impact of new technology on the management of pa-
tients with significant (>70% stenosis) coronary artery disease (CAD). we
compared treatment strategies in patients undergoing diagnostic cardiac
catheterization during the years 1987-1989 (group 1) and 1992-1994 (group
21. Patients with significant congenital and valvular disease, left main dis-
ease, and insignificant coronary artery disease were excluded from analysis.
Although there was a higher prevalance of hypertension (60.6% vs 66.6%,
P = 0.024), hypercholesterolemia (32.5% vs 51.5%, P = 0.001), and female
gender (27% vs 33%, P < 0.001), and a lower prevalance of unstable angina
at the time of the procedure (26.8% vs 17.9%. P = 0.001) in group 2, there
were no differences between the two groups in mean age (61 .0 yrs vs 62.5
yrs), incidence of diabetes (26.5% vs 25.2%), tobacco use (58.4% vs 56.1 %1,
peripheral vascular disease (16.3% vs 17.3% 1or cerebrovascular disease
(7.8% vs 6.8%). Although there were more female patients in group 2, the
percent of women and men undergoing revascularization was similar. Treat-
ment strategies were classified as either medical therapy; percutaneous
revascularization; or coronary artery bypass surgery (CABG).
Group 111987-1989J Group 2[1992-19941 p
n (%) n (%) value
Despite technologic advances in percutaneous revascularization, the per-
centage of patients undergoing percutaneous revascularization has not in-
creased. There has been a significant reduction in the percentage of patients
referred for CABG, which may be due to an increasing number of patients
being treated medically. This change in treatment strategy may reflect better
medical therapy and/or increased concern about the risks of revasculariza-
tion.
In conclusion, Troponin T measurements in patients with acute ischemic
syndromes can stratify patients into high and low risk categories. Early and
rapid determination of Troponin T levels has the potential to streamline health
care delivery in patients with acute ischemic syndromes.
9:45
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Assessing Coronary Reperfusion After Thrombolytic
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Robert H. Christenson, E. Magnus Ohman, Kristina N. Sigmon, Mary
Ann O'Hanesian, Gladys L. Alonsozana, Kristin L. Newby, Show-Hong DUh,
Mitchell W. Krucoff, Robert M. Califf, TAMI Study Group. Univ of Maryland,
Baltimore, MD & Duke Univ., Durham, NC
Myoglobin (MYO), measured using a quantitative 10 minute assay, was ex-
amined in combination with clinical variables for assessing infarct related
artery (IRA) patency in 96 MI pts, all of whom received front-loaded throm-
Medical Therapy
Percutaneous Revascularization
CABG
573 (38%)
453 (30%)
490 (32%)
808 (49'10)
472(29%)
370 (22%)
0.001
NS
0.001
